LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

34.23 -3.06

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

34.23

Max

34.23

Galvenie mērījumi
By Trading Economics
Ienākumi	11M 51M
Pārdošana	39M 239M
P/E Sektora vidējais	11.36 110.024
EPS	1.08
Peļņas marža	21.242
Darbinieki	268
EBITDA	14M 73M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+40.3% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 24. febr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	387M 2.1B
Iepriekšējā atvēršanas cena	37.29
Iepriekšējā slēgšanas cena	34.23

Ziņu noskaņojums

By Acuity

50%

159 / 351 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 20. febr. 17:37 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026. g. 20. febr. 16:18 UTC

Galvenie tirgus virzītāji

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026. g. 20. febr. 23:12 UTC

Iegādes, apvienošanās, pārņemšana

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026. g. 20. febr. 22:12 UTC

Peļņas

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 20. febr. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 20. febr. 21:23 UTC

Peļņas

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026. g. 20. febr. 21:20 UTC

Tirgus saruna

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026. g. 20. febr. 21:01 UTC

Iegādes, apvienošanās, pārņemšana

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026. g. 20. febr. 20:38 UTC

Tirgus saruna

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026. g. 20. febr. 20:17 UTC

Tirgus saruna

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026. g. 20. febr. 20:11 UTC

Tirgus saruna

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026. g. 20. febr. 19:59 UTC

Tirgus saruna

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026. g. 20. febr. 19:58 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026. g. 20. febr. 19:49 UTC

Tirgus saruna

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026. g. 20. febr. 19:09 UTC

Tirgus saruna

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026. g. 20. febr. 19:00 UTC

Tirgus saruna

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026. g. 20. febr. 18:28 UTC

Tirgus saruna

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026. g. 20. febr. 18:20 UTC

Tirgus saruna

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026. g. 20. febr. 18:05 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 18:04 UTC

Tirgus saruna

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026. g. 20. febr. 17:38 UTC

Tirgus saruna

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 17:24 UTC

Tirgus saruna

Correction to Treasury Yields Fall Market Talk

2026. g. 20. febr. 17:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 20. febr. 16:53 UTC

Tirgus saruna

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 20. febr. 16:45 UTC

Tirgus saruna

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026. g. 20. febr. 16:40 UTC

Tirgus saruna

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

40.3% augšup

Prognoze 12 mēnešiem

Vidējais 48.25 USD 40.3%

Augstākais 55 USD

Zemākais 42 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 5 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

159 / 351 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.